eligibility_summary
Eligible: Adults 18–75 with untreated, CD20+ grade 1–3a follicular lymphoma, bulky (≥7 cm), stage II–IV, meeting GELF, ECOG 0–2, adequate blood counts, renal (CrCl ≥50), hepatic (bili ≤1.5×ULN, AST/ALT ≤2.5×ULN), life expectancy ≥6 months, contraception, consent. Exclude: CNS disease, transformed/grade 3b, recent other cancers, HIV/HBV/HCV or serious infection (incl JC), NYHA III/IV or LVEF<50%, active/interstitial/drug-induced pneumonia, serious neuro/psychiatric illness, or investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase II in untreated bulky follicular lymphoma: localized radiotherapy (18–24 Gy) followed by six cycles of tiselizumab + R-CHOP, with rituximab maintenance for responders. Interventions and mechanisms: Radiotherapy—induces DNA double-strand breaks, debulking and immunogenic cell death, Tiselizumab—anti-PD-1 IgG4 monoclonal antibody (immune checkpoint inhibitor) restoring T-cell activity, Rituximab—anti-CD20 monoclonal antibody depleting B cells via ADCC/CDC/apoptosis, Cyclophosphamide—alkylating agent (DNA crosslinks), Doxorubicin—anthracycline/topoisomerase II inhibitor, Vincristine—vinca alkaloid microtubule inhibitor, Prednisone—glucocorticoid with lympholytic effects. Targets/pathways: CD20+ malignant B cells, PD-1 on T cells, DNA replication/repair and mitotic spindle pathways, immune effector mechanisms.